Targeting the JAK/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation
Frontiers in Immunology · 21.08.2026 · 17
DOI: 10.3389/fimmu.2026.1887876 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 21.08.2026. Verfasst von Nathalie Garnier und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's…. Hauptthemen laut MEDLINE: STAT Transcription Factors, Janus Kinases, Janus Kinase Inhibitors, Virus Diseases. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIA NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
The discovery of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway as a key regulator of immune function and inflammation led to the development of JAK inhibitors (JAK-i), several of which are now approved for autoimmune and chronic inflammatory conditions. Recently, JAK-i have been repurposed for infectious diseases, most notably with baricitinib, a United States Food and Drug Administration (FDA)-approved JAK1/2 inhibitor for individuals hospitalized for COVID-19, demonstrating a survival benefit by dampening cytokine-mediated hyperinflammation. This has generated increased interest in leveraging JAK-i for treating people with viral infections associated with chronic immune activation, inflammation or viral persistence. This review summarizes JAK/STAT signaling in viral infections characterized by latency or chronic sequelae. We explore how modulation of this pathway may alter immune responses, impact viral control, and mitigate the consequences of chronic inflammation. We also critically examine the therapeutic potential and limitations of JAK-i in these contexts. Finally, we outline key gaps in the field and propose future directions for research into JAK/STAT targeted immunomodulation in chronic viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, United States.
- Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, United States.
- Department of Global Health, Rollins School of Public Health, Atlanta, GA, United States.
- Emory Vaccine Center, Emory University, Atlanta, GA, United States.
- The Joseph Maxwell Cleland Atlanta VA Medical Center, The Atlanta Veterans Affairs Medical Center, Decatur, GA, United States.
Förderung
- NIAID NIH HHS
- NIA NIH HHS
- NIMH NIH HHS
Zitieren
APA
Garnier, N., Ossi, J., Marconi, V. C., Schinazi, R. F., & Titanji, B. K. (2026). Targeting the JAK/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1887876
Vancouver
Garnier N, Ossi J, Marconi VC, Schinazi RF, Titanji BK. Targeting the JAK/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1887876
BibTeX
@article{Garnier2026,
author = {Garnier, Nathalie and Ossi, Julia and Marconi, Vincent C and Schinazi, Raymond F and Titanji, Boghuma K},
title = {Targeting the JAK/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1887876}
}
EUVIMED